FDA sets public meeting and requests comment on autism medication development

The Food and Drug Administration (FDA) has announced the opportunity for public comment on Patient‐Focused Drug Development for autism. The public meeting is intended to allow the FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism. The public meeting will be held on May 4, 2017, from 1 to 5 p.m. at the FDA's White Oak Campus in Silver Spring, Maryland. Registration to attend the meeting must be received by April 24. Electronic comments must be submitted on or before July 5.
Source: The Brown University Child and Adolescent Psychopharmacology Update - Category: Psychiatry Tags: News Source Type: research